$VIGL
Vigil Neuroscience, Inc. Stock $vigl

$vigl Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000095017024036158 Filed on March 26, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$7.089M	$7.075M	$27.93M
YoY Change	2.13%	5.88%	30.28%
% of Gross Profit
Research & Development	$14.33M	$16.78M	$60.93M
YoY Change	3.56%	37.66%	28.43%
% of Gross Profit
Depreciation & Amortization	$113.0K	$109.0K	$399.0K
YoY Change	85.25%	419.05%	600.0%
% of Gross Profit
Operating Expenses	$21.42M	$23.86M	$88.87M
YoY Change	3.08%	26.41%	29.01%
Operating Profit	-$21.42M		-$88.87M
YoY Change	3.08%		29.01%
Interest Expense	$1.477M	$1.681M	$6.241M
YoY Change	49.95%	294.6%	901.77%
% of Operating Profit
Other Income/Expense, Net	$1.475M	$2.000K	-$13.00K
YoY Change	50.51%	-122.22%	-102.25%
Pretax Income	-$19.94M	-$22.17M	-$82.64M
YoY Change	0.73%	20.15%	20.98%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$19.94M	-$22.17M	-$82.64M
YoY Change	0.73%	20.15%	20.98%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.50		-$2.13
Diluted Earnings Per Share	-$0.50	-$0.57	-$2.14
COMMON SHARES
Basic Shares Outstanding	36.88M	35.88M	38.71M
Diluted Shares Outstanding	39.86M		38.71M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$101.6M	$117.9M	$117.9M
YoY Change	-38.2%	-36.8%	-36.8%
Cash & Equivalents	$51.76M	$51.99M	$51.99M
Short-Term Investments	$49.88M	$65.95M	$65.95M
Other Short-Term Assets	$910.0K	$3.967M	$3.967M
YoY Change	-33.04%	531.69%	-64.58%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$106.5M	$121.9M	$121.9M
YoY Change	-38.13%	-38.37%	-38.37%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.637M	$17.94M	$17.94M
YoY Change	-14.47%	1415.29%	1186.09%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$126.0K	$1.010M	$1.010M
YoY Change	-86.41%	279.7%	-15.34%
Total Long-Term Assets	$18.54M	$18.95M	$18.95M
YoY Change	-7.99%	632.26%	632.26%
TOTAL ASSETS
Total Short-Term Assets	$106.5M	$121.9M	$121.9M
Total Long-Term Assets	$18.54M	$18.95M	$18.95M
Total Assets	$125.1M	$140.9M	$140.9M
YoY Change	-34.98%	-29.71%	-29.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.491M	$1.946M	$1.946M
YoY Change	-31.16%	0.21%	0.21%
Accrued Expenses	$7.112M	$9.715M	$9.715M
YoY Change	36.43%	3.94%	3.94%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Short-Term Liabilities	$8.603M	$11.66M	$11.66M
YoY Change	16.4%	3.09%	3.09%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$12.69M	$12.95M	$12.95M
YoY Change	-6.87%
Total Long-Term Liabilities	$12.69M	$12.95M	$12.95M
YoY Change	-6.87%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.603M	$11.66M	$11.66M
Total Long-Term Liabilities	$12.69M	$12.95M	$12.95M
Total Liabilities	$21.30M	$24.61M	$24.61M
YoY Change	1.31%	117.52%	117.52%
SHAREHOLDERS EQUITY
Retained Earnings	-$242.7M	-$222.8M
YoY Change	51.78%	59.03%
Common Stock	$346.5M	$339.0M
YoY Change	4.64%	2.98%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$103.8M	$116.3M	$116.3M
YoY Change
Total Liabilities & Shareholders Equity	$125.1M	$140.9M	$140.9M
YoY Change	-34.98%	-29.71%	-29.71%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$19.94M	-$22.17M	-$82.64M
YoY Change	0.73%	20.15%	20.98%
Depreciation, Depletion And Amortization	$113.0K	$109.0K	$399.0K
YoY Change	85.25%	419.05%	600.0%
Cash From Operating Activities	-$21.88M	-$15.51M	-$70.36M
YoY Change	-1.37%	-9.21%	8.0%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$14.00K	$674.0K
YoY Change	-100.0%	-94.85%	-26.82%
Acquisitions
YoY Change
Other Investing Activities	$16.47M	$10.67M	-$64.46M
YoY Change	-124.03%
Cash From Investing Activities	$16.47M	$10.65M	-$65.14M
YoY Change	-123.86%	-4016.18%	6972.53%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$911.0K
YoY Change			-98.2%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	5.184M	48.00K	888.0K
YoY Change	2453.69%	-52.48%	-99.45%
NET CHANGE
Cash From Operating Activities	-21.88M	-15.51M	-70.36M
Cash From Investing Activities	16.47M	10.65M	-65.14M
Cash From Financing Activities	5.184M	48.00K	888.0K
Net Change In Cash	-231.0K	-4.813M	-134.6M
YoY Change	-99.75%	-72.11%	-241.42%
FREE CASH FLOW
Cash From Operating Activities	-$21.88M	-$15.51M	-$70.36M
Capital Expenditures	$0.00	$14.00K	$674.0K
Free Cash Flow	-$21.88M	-$15.53M	-$71.04M
YoY Change	-3.51%	-10.55%	7.52%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001827087
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2023Q4	us-gaap	Investment Type Extensible Enumeration InvestmentTypeExtensibleEnumeration	http://www.vigilneuro.com/20231231#MarketableSecuritiesMember
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-41200
CY2023	dei	Entity Registrant Name EntityRegistrantName	VIGIL NEUROSCIENCE, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-1880494
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	100 Forge Road,
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 700
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Watertown
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02472
CY2023	dei	City Area Code CityAreaCode	857
CY2023	dei	Local Phone Number LocalPhoneNumber	254-4445
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2023	dei	Trading Symbol TradingSymbol	VIGL
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	233100000
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	36884712
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	vigl	Rule10 B51 Arr Modified Flag Rule10B51ArrModifiedFlag	false
CY2023Q4	vigl	Non Rule10 B51 Arr Modified Flag NonRule10B51ArrModifiedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	238
CY2023	dei	Auditor Name AuditorName	PricewaterhouseCoopers LLP
CY2023	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	51992000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	186605000
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	65948000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3967000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11200000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	121907000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	197805000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1745000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1184000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	16147000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	141000
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	49000
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	70000
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	927000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	927000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	83000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	266000
CY2023Q4	us-gaap	Assets Assets	140858000
CY2022Q4	us-gaap	Assets Assets	200393000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1946000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1942000
CY2023Q4	vigl	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	8810000
CY2022Q4	vigl	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	9194000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	905000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	153000
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	23000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11661000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11312000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	12945000
CY2023Q4	us-gaap	Liabilities Liabilities	24606000
CY2022Q4	us-gaap	Liabilities Liabilities	11312000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	35929035
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	35664658
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	35884712
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	35620335
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	4000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	4000
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	339025000
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	329211000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-5000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-222772000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-140134000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	116252000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	189081000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	140858000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	200393000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	60934000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	47444000
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	27932000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	21440000
CY2023	us-gaap	Operating Expenses OperatingExpenses	88866000
CY2022	us-gaap	Operating Expenses OperatingExpenses	68884000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-88866000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-68884000
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	6241000
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	623000
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-13000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-44000
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6228000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	579000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-82638000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-68305000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.13
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.13
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.16
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.16
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38712207
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38712207
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31685125
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31685125
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-82638000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-68305000
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-5000
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-82643000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-68305000
CY2023	vigl	Research And Development Expense Related Party ResearchAndDevelopmentExpenseRelatedParty	50000
CY2022	vigl	Research And Development Expense Related Party ResearchAndDevelopmentExpenseRelatedParty	295000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-69443000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	20678000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	154000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5477000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-68305000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	189081000
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	911000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8903000
CY2023	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	-5000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-82638000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	116252000
CY2023	us-gaap	Profit Loss ProfitLoss	-82638000
CY2022	us-gaap	Profit Loss ProfitLoss	-68305000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	8903000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	5477000
CY2023	vigl	Non Cash Operating Lease Expense NonCashOperatingLeaseExpense	1364000
CY2022	vigl	Non Cash Operating Lease Expense NonCashOperatingLeaseExpense	932000
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	399000
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	78000
CY2023	vigl	Amortization Of Premium Discount On Marketable Securities AmortizationOfPremiumDiscountOnMarketableSecurities	-1481000
CY2023	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	8000
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-4183000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3680000
CY2023	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	83000
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	259000
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	5000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2478000
CY2023	vigl	Increase Decrease In Accrued Expenses And Other Current Liabilities IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities	-384000
CY2022	vigl	Increase Decrease In Accrued Expenses And Other Current Liabilities IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities	3995000
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-623000
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-909000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-70363000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-65149000
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	147468000
CY2023	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	83004000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	674000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	921000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-65138000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-921000
CY2022	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	89872000
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	50594000
CY2022	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	20678000
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	23000
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	43000
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	911000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	154000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	888000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	161255000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-134613000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	95185000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	187532000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	92347000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	52919000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	187532000
CY2022	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	161939000
CY2022	vigl	Deferred Offering Costs Paid In The Prior Year DeferredOfferingCostsPaidInThePriorYear	1887000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	14319000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	192000
CY2023	vigl	Prepaid Rent Reclassified To Right Of Use Assets PrepaidRentReclassifiedToRightOfUseAssets	2887000
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	116000
CY2023Q4	vigl	Cash Cash Equivalents And Marketable Securities CashCashEquivalentsAndMarketableSecurities	117900000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-222800000
CY2022Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	88000000
CY2023Q1	vigl	Maximum Stock Value To Be Issued Under Agreement MaximumStockValueToBeIssuedUnderAgreement	100000000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1184000
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, research and development expenses and related prepaid or accrued costs and stock-based compensation. The Company bases its estimates on historical experience, known trends and other market-specific or relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	51992000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	186605000
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	927000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	927000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	52919000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	187532000
CY2023Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	0
CY2022Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	0
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk and Off-Balance Sheet Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains its cash and cash equivalents with high quality, accredited financial institutions and, accordingly, such funds are subject to minimal credit risk. The Company has no significant off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is dependent on third-party organizations to manufacture and process its therapeutic candidates for its development programs. In particular, the Company relies on a single third-party contract manufacturer, Fujifilm Diosynth Biotechnologies U.S.A., Inc. and Fujifilm Diosynth Biotechnologies Texas, LLC (collectively, “FUJIFILM”), to produce clinical supply and process its current product candidate, VGL101 ("iluzanebart"). The Company expects to continue to be dependent on a small number of manufacturers to supply it with its requirements for all products. The Company’s research and development programs, including any associated potential commercialization efforts, could be adversely affected by a significant interruption in the supply of the necessary materials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is dependent on a limited number of third parties that provide license rights used by the Company in the development and potential commercialization of its therapeutic candidates and programs. From inception through December 31, 2023, the Company’s research and development programs primarily relate to rights conveyed by Amgen, Inc. (“Amgen”) (see Note 12). The Company could experience delays in the development and potential commercialization of its therapeutic candidates and programs if the Amgen license arrangement or any other license agreement utilized in the Company’s research and development activities is terminated, if the Company fails to meet the obligations required under its arrangements, or if the Company is unable to successfully secure new strategic alliances or licensing agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2195000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1256000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	450000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	72000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1745000
CY2023	us-gaap	Depreciation Depreciation	378000
CY2022	us-gaap	Depreciation Depreciation	57000
CY2023Q4	us-gaap	Investment Owned At Cost InvestmentOwnedAtCost	65953000
CY2023Q4	vigl	Investment Unrealized Gain InvestmentUnrealizedGain	36000
CY2023Q4	vigl	Investment Unrealized Losses InvestmentUnrealizedLosses	41000
CY2023Q4	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue	65948000
CY2023Q4	vigl	Number Of Securities NumberOfSecurities	27
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	14
CY2023	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded	0
CY2023Q4	vigl	Prepaid Research And Development Expense Current PrepaidResearchAndDevelopmentExpenseCurrent	1563000
CY2022Q4	vigl	Prepaid Research And Development Expense Current PrepaidResearchAndDevelopmentExpenseCurrent	6670000
CY2022Q4	vigl	Construction Related Prepaid Assets Current ConstructionRelatedPrepaidAssetsCurrent	3769000
CY2023Q4	us-gaap	Other Receivables OtherReceivables	1137000
CY2022Q4	us-gaap	Other Receivables OtherReceivables	15000
CY2023Q4	us-gaap	Interest Receivable InterestReceivable	348000
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	122000
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	133000
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	797000
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	613000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3967000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11200000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5477000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4208000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3512000
CY2023Q4	vigl	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	3278000
CY2022Q4	vigl	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	2894000
CY2022Q4	us-gaap	Construction Payable Current ConstructionPayableCurrent	1416000
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1000000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	986000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	324000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	386000
CY2023Q4	vigl	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	8810000
CY2022Q4	vigl	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	9194000
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8900000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5500000
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8903000
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6233291
CY2023	us-gaap	Common Stock Voting Rights CommonStockVotingRights	Each share of common stock entitles the holder to one vote for each share of common stock held.
CY2023	us-gaap	Dividends Common Stock DividendsCommonStock	0
CY2022	us-gaap	Dividends Common Stock DividendsCommonStock	0
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	10922405
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	9390736
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-82638000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-68305000
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38712207
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38712207
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31685125
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31685125
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.13
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.13
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.16
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.16
CY2023	vigl	Pre Funded Warrants Remaining Unfunded Exercise Price PreFundedWarrantsRemainingUnfundedExercisePrice	0.0001
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4523824
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.062
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.061
CY2023	vigl	Effective Income Tax Rate Reconciliation Other Permanent Differences EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences	-0.006
CY2022	vigl	Effective Income Tax Rate Reconciliation Other Permanent Differences EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences	-0.005
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.058
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.047
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.324
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.313
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	26310000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	18648000
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	9582000
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	4786000
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	4977000
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	5406000
CY2023Q4	vigl	Deferred Tax Assets Start Up Costs DeferredTaxAssetsStartUpCosts	79000
CY2022Q4	vigl	Deferred Tax Assets Start Up Costs DeferredTaxAssetsStartUpCosts	85000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	7622000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	2276000
CY2023Q4	vigl	Deferred Tax Assets Capitalized Research And Development Expenses DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses	24283000
CY2022Q4	vigl	Deferred Tax Assets Capitalized Research And Development Expenses DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses	11048000
CY2023Q4	vigl	Deferred Tax Assets Depreciation DeferredTaxAssetsDepreciation	657000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	73510000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	42249000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	69087000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	42176000
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	4423000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	73000
CY2022Q4	vigl	Deferred Tax Liabilities Depreciation DeferredTaxLiabilitiesDepreciation	15000
CY2023Q4	vigl	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	4423000
CY2022Q4	vigl	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	58000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	69100000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1910000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	42200000
CY2023	vigl	Cumulative Change In Ownership Percentage CumulativeChangeInOwnershipPercentage	0.50
CY2023	vigl	Period For Cumulative Change In Ownership PeriodForCumulativeChangeInOwnership	P3Y
CY2023	vigl	Research And Development Credit Carryforwards Expiration Start Year ResearchAndDevelopmentCreditCarryforwardsExpirationStartYear	2040
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	26900000
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	21400000
CY2023Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0
CY2023	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2023Q4	vigl	Pending Tax Examinations PendingTaxExaminations	0
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	14300000
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	17300000
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	2400000
CY2023	us-gaap	Variable Lease Payment VariableLeasePayment	800000
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	2435000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	960000
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	38000
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	755000
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	67000
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	21000
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	21000
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	2000
CY2023	vigl	Finance Lease Cost FinanceLeaseCost	21000
CY2022	vigl	Finance Lease Cost FinanceLeaseCost	23000
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	1707000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	937000
CY2022	vigl	Operating Lease Payment From Finace Lease OperatingLeasePaymentFromFinaceLease	2000
CY2023	vigl	Financing Cash Flows From Finance Leases FinancingCashFlowsFromFinanceLeases	23000
CY2022	vigl	Financing Cash Flows From Finance Leases FinancingCashFlowsFromFinanceLeases	43000
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y10M24D
CY2023Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0757
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1968000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2027000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2088000
CY2023Q4	vigl	Lessee Operating Lease Liability Payments Due Year Five And Thereafter LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter	11269000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	19262000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	5412000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	13850000
CY2022	vigl	Number Of Pending Material Litigation Or Other Material Legal Proceedings NumberOfPendingMaterialLitigationOrOtherMaterialLegalProceedings	0
CY2021	vigl	Number Of Pending Material Litigation Or Other Material Legal Proceedings NumberOfPendingMaterialLitigationOrOtherMaterialLegalProceedings	0
CY2023	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	500000
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	300000

Files In Submission

Name	View Source	Status
0000950170-24-036158-index-headers.html	Edgar Link	pending
0000950170-24-036158-index.html	Edgar Link	pending
0000950170-24-036158.txt	Edgar Link	pending
0000950170-24-036158-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img212263187_0.jpg	Edgar Link	pending
img212263187_1.jpg	Edgar Link	pending
img212263187_2.jpg	Edgar Link	pending
img212263187_3.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vigl-20231231.htm	Edgar Link	pending
vigl-20231231.xsd	Edgar Link	pending
vigl-ex23_1.htm	Edgar Link	pending
vigl-ex31_1.htm	Edgar Link	pending
vigl-ex31_2.htm	Edgar Link	pending
vigl-ex32_1.htm	Edgar Link	pending
vigl-ex32_2.htm	Edgar Link	pending
vigl-ex97.htm	Edgar Link	pending
vigl-20231231_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VIGL
Vigil Neuroscience, Inc. Stock $vigl

2024 Q1 Form 10-K Financial Statement

#000095017024036158 Filed on March 26, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VIGL Vigil Neuroscience, Inc. Stock $vigl

2024 Q1 Form 10-K Financial Statement

#000095017024036158 Filed on March 26, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VIGL
Vigil Neuroscience, Inc. Stock $vigl